linkedin
 
You Are On
Equity
Equity Analysis
News Analysis
Corporate Action
Corporate Info
Derivatives
Other Market
Research
 
 Board Meetings  
Morepen Laboratories Ltd.
 
Source DateBoard Meeting DateDetails
21 May 202626 May 2026 Quarterly Results (Revised) & Final Dividend (Revised) & Audited Results
15 May 202622 May 2026 Audited Results & Quarterly Results
03 Feb 202610 Feb 2026 Quarterly Results
07 Nov 202514 Nov 2025 Quarterly Results
01 Aug 202506 Aug 2025 Quarterly Results
05 May 202512 May 2025 Audited Results & Quarterly Results & Final Dividend
03 Feb 202506 Feb 2025 Quarterly Results
06 Nov 202411 Nov 2024 Quarterly Results
07 Aug 202412 Aug 2024 Final Dividend(Cancelled) & Quarterly Results
14 May 202421 May 2024 Audited Results
19 Feb 202422 Feb 2024 Inter alia, consider and approve the following matters: 1. To evaluate proposals for fund raising by the Company, by way of, inter-alia, issue of securities including equity shares or any other equity linked instruments or securities including nonconvertible debt instruments along with warrants and convertible securities other than warrants or any other eligible securities by way of, inter-alia, a preferential allotment or a private placement (including one or more qualified institutions placements or further public issue of equity, in accordance with the applicable provisions of the Companies Act, 2013 and its rules made thereunder and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or through any other permissible mode, in such manner, and on such terms and conditions as may be deemed appropriate by the Board of Directors, including committee thereof, in its absolute discretion, subject to the receipt of necessary approvals, including the approval of the members of the Company at general meetings or through postal ballot and such other parties including regulatory and statutory approvals as may be required; 2. The notice of Extra-Ordinary General Meeting of the Company or Postal Ballot Notice along with explanatory statement thereto, inter-alia, for seeking approval of the members of the Company in relation to the above fund-raising proposal.
24 Jan 202431 Jan 2024 Quarterly Results
26 Oct 202302 Nov 2023 Quarterly Results
31 Jul 202305 Aug 2023 Quarterly Results
09 May 202316 May 2023 Audited Results
06 Feb 202313 Feb 2023 Quarterly Results
03 Nov 202210 Nov 2022 Quarterly Results
22 Jul 202229 Jul 2022 Quarterly Results
28 Apr 202205 May 2022 Audited Results
20 Jan 202208 Feb 2022 Quarterly Results Inter alia, to consider and approve: (2) Variation/alteration of preference shareholders? rights, by converting said unlisted preference shares into Compulsorily Convertible Preference Shares and issuance of Equity Shares arising on conversion thereof, subject to the approval of preference shareholders, equity shareholders and such other regulatory, statutory authority(ies), as may be required.
Page 1 of 6
Prev || Next
 
RMS | Policies & Procedures| PMLA | Disclaimer | Privacy Policy | Web Mail | Relationship | Investor Grievance
Career | Contact Us| KYC| PMS Risk Disclosure | Key Managerial Person | Basic Details | Process of Opening an Account | Process of Filing Complaint
Links to MCX | NCDEX |FMC | NCDEX CMID NCDEX-CO-04-00129 | MCX 10550 | FMC MCX: MCX/TCM/CORP/0008| FMC NCDEX : NCDEX/TCM/CORP/0274    
NSE: INB230914036 |NSE F & O INF230914036 |BSE: INB010914032 |BSE F & O: INF010914032 | CDSL: IN-DP-CDSL-335-2006 | OTC: INB200914032
Related Sites: Bombay Stock Exchange (BSE), Investor Protection, National Stock Exchange (NSE), Securities & Exchange Board of India (SEBI)
© Padmakshi 2009. All Rights Reserved. Designed || Developed & Content Powered By Accord Fintech Pvt. Ltd.